IGMS Projected Dividend Yield
IGM Biosciences Inc ( NASDAQ : IGMS )IGM Biosciences is a clinical-stage biotechnology company engaging in the development of Immunoglobulin M (IgM) antibodies for the treatment of cancer, autoimmune and inflammatory diseases and infectious diseases. Co.'s product candidates include: IGM-8444, which is an IgM antibody targeting Death Receptor 5 proteins for the treatment of patients with solid and hematologic malignancies; Imvotamab, which is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 proteins; IGM-7354, which is an IgM antibody targeting the delivery of interleukin-15 to the area of PD-L1 expressing cells; and IGM-2644, which is a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins. 20 YEAR PERFORMANCE RESULTS |
IGMS Dividend History Detail IGMS Dividend News IGMS Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |